|
CA2213567C
(en)
*
|
1995-02-24 |
2010-01-26 |
Stuart L. Weg |
Use of ketamine for facilitating detoxification and treatment of smoking addiction, and device therefor
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
EP1551393A4
(en)
|
2002-07-30 |
2010-06-16 |
Peter Migaly |
COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
CA2506615A1
(en)
*
|
2002-11-18 |
2004-06-03 |
Yaupon Therapeutics, Inc. |
Analgesic uses of norketamine and ketamine/norketamine prodrugs
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
ATE433993T1
(de)
|
2003-02-26 |
2009-07-15 |
Univ Johns Hopkins |
Modulatorische verbindungen und verfahren für glutamattransport
|
|
AU2004229551A1
(en)
|
2003-04-14 |
2004-10-28 |
Pain Therapeutics, Inc. |
Methods for the treatment of pain comprising opioid antagonists
|
|
CA2563707A1
(en)
|
2004-04-20 |
2005-11-03 |
Pfizer Inc. |
Method of treating neuropathic pain using a crth2 receptor antagonsit
|
|
EP1799264A2
(en)
|
2004-10-08 |
2007-06-27 |
Neuromolecular Pharmaceuticals Inc |
Methods and compositions for treating migraine pain
|
|
US20080096872A1
(en)
|
2004-12-22 |
2008-04-24 |
Friedman Robert S |
Composition for Treatment of Pain Specification
|
|
US20090111837A1
(en)
|
2005-03-01 |
2009-04-30 |
Peter Cox |
Use of pde7 inhibitors for the treatment of neuropathic pain
|
|
CN101155548A
(zh)
|
2005-03-04 |
2008-04-02 |
曼提斯库拉Ehf.公司 |
评估神经病症的方法和系统
|
|
JP5666087B2
(ja)
|
2005-04-06 |
2015-02-12 |
アダマス・ファーマシューティカルズ・インコーポレーテッド |
Ｃｎｓ関連疾患の治療のための方法及び組成物
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
EP1971372B1
(en)
|
2005-12-19 |
2018-11-14 |
PharmaIN Corporation |
Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
|
|
CN101466364A
(zh)
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
|
US20090306137A1
(en)
|
2006-05-22 |
2009-12-10 |
Wolfgang Curt D |
Treatment for depressive disorders
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
AU2008279572A1
(en)
|
2007-02-01 |
2009-01-29 |
David Chau |
Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
ES2693948T3
(es)
|
2007-03-15 |
2018-12-14 |
Auspex Pharmaceuticals, Inc. |
Fenetilamina sustituida con actividad serotoninérgica y/o norepinefrinérgica
|
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
US20100316678A1
(en)
|
2007-06-28 |
2010-12-16 |
Cnsbio Pty Ltd. |
Combination methods and compositions for treatment of neuropathic pain
|
|
EP2178584A2
(en)
|
2007-07-26 |
2010-04-28 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
|
WO2009021058A2
(en)
|
2007-08-06 |
2009-02-12 |
Trinity Labortories, Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
|
JP2010540454A
(ja)
|
2007-09-21 |
2010-12-24 |
アカディア ファーマシューティカルズ，インコーポレーテッド |
ピマバンセリンと他の薬剤との併用投与
|
|
JP2011507800A
(ja)
|
2007-12-26 |
2011-03-10 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
癲癇、精神障害、または感覚器官の障害のためのａｍｐａ受容体アンタゴニスト
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
TR201902233T4
(tr)
|
2009-10-30 |
2019-03-21 |
Ix Biopharma Ltd |
Hızlı çözünen katı dozaj formu.
|
|
US9895077B2
(en)
|
2010-01-18 |
2018-02-20 |
Elminda Ltd. |
Method for diagnosing a brain related disorder using brain network activity patterns
|
|
US9073819B2
(en)
|
2011-06-30 |
2015-07-07 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
JP2015501652A
(ja)
|
2011-12-14 |
2015-01-19 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｇａｂｒ−ａ２診断
|
|
WO2013138322A1
(en)
*
|
2012-03-12 |
2013-09-19 |
Janssen Pharmaceutica Nv |
Esketamine for the treatment of treatment-refractory or treatment-resistant depression
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
AU2013305580A1
(en)
|
2012-08-23 |
2015-04-09 |
Stuart L. Weg |
Anxiolytic composition, formulation and method of use
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
JP6391120B2
(ja)
|
2012-12-20 |
2018-09-19 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
ニューロテンシン受容体１の小分子アゴニスト
|
|
US20140275278A1
(en)
|
2013-03-15 |
2014-09-18 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
SG11201507358VA
(en)
|
2013-03-15 |
2015-10-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical composition of s-ketamine hydrochloride
|
|
CA2907566C
(en)
|
2013-04-01 |
2023-08-22 |
Pulmatrix, Inc. |
Tiotropium dry powders
|
|
WO2015031410A1
(en)
|
2013-08-26 |
2015-03-05 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
HRP20211629T1
(hr)
|
2013-09-13 |
2022-02-04 |
National University Corporation Chiba University |
Primjena r-ketamina i njegove soli kao lijekova
|
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
EP3287124B1
(en)
|
2014-04-17 |
2022-11-30 |
Ketabon GmbH |
Oral dosage form of ketamine
|
|
WO2015171770A1
(en)
|
2014-05-06 |
2015-11-12 |
Northwestern University |
Combinations of nmdar modulating compounds
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
EP3179993B1
(en)
|
2014-08-13 |
2021-01-20 |
Janssen Pharmaceutica NV |
Esketamine for use in a method for the treatment of depression
|
|
CA2961208A1
(en)
|
2014-09-15 |
2016-03-24 |
Janssen Pharmaceutica Nv |
Val66met (snp rs6265) genotype specific dosing regimens and methods for the treatment of depression
|
|
AU2015330905B2
(en)
|
2014-10-07 |
2021-02-25 |
AI Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
RU2771275C2
(ru)
|
2014-11-04 |
2022-04-29 |
Аморса Терапьютикс, Инк. |
Нейро-аттенуирующие кетаминовые и норкетаминовые соединения, их производные и способы их получения
|
|
CA2970065A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
US20180015054A1
(en)
|
2014-12-31 |
2018-01-18 |
Icahn School Of Medicine At Mount Sinai |
Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
|
|
WO2016112467A1
(en)
|
2015-01-15 |
2016-07-21 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
US10991449B2
(en)
|
2015-06-12 |
2021-04-27 |
Indiana University Research And Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
AU2016288188B2
(en)
|
2015-06-27 |
2021-08-05 |
Shenox Pharmaceuticals, Llc |
Ketamine transdermal delivery system
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
KR20180102052A
(ko)
|
2015-10-16 |
2018-09-14 |
노오쓰웨스턴 유니버시티 |
조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
WO2017087691A1
(en)
|
2015-11-17 |
2017-05-26 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
AU2017238858A1
(en)
|
2016-03-25 |
2018-10-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of using (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
|
|
CN109475500A
(zh)
|
2016-05-25 |
2019-03-15 |
财团法人卫生研究院 |
用于减低氯胺酮致精神病状副作用及成瘾疾患的方法与组合物
|
|
KR20240027874A
(ko)
|
2016-07-28 |
2024-03-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Gpr156 변이체 및 이들의 용도
|
|
WO2018025089A2
(en)
|
2016-08-05 |
2018-02-08 |
Shin Nippon Biomedical Laboratories, Ltd. |
Pharmaceutical compositions
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
US20190240184A1
(en)
|
2016-10-27 |
2019-08-08 |
National University Corporation Chiba University |
Pharmaceutical applications for (s)-norketamine and salts thereof
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
US20200030251A1
(en)
|
2017-04-20 |
2020-01-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
EP3635130A4
(en)
|
2017-05-12 |
2021-06-09 |
Indiana University Research and Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
KR102608479B1
(ko)
|
2017-05-25 |
2023-12-01 |
글리테크 엘엘씨. |
Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
WO2018234568A2
(en)
|
2017-06-23 |
2018-12-27 |
Develco Pharma Schweiz Ag |
HYDROXYNORKETAMINE FOR USE IN TREATING DEPRESSION
|
|
AU2018319592B2
(en)
|
2017-08-20 |
2024-06-27 |
Nasus Pharma Ltd. |
Dry powder compositions for intranasal delivery
|
|
US20210315840A1
(en)
|
2017-09-25 |
2021-10-14 |
Small Pharma Ltd |
Solid oral dosage forms of ketamine derivatives
|
|
JP7265990B2
(ja)
|
2017-09-27 |
2023-04-27 |
国立大学法人千葉大学 |
神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
CA3079560A1
(en)
|
2017-10-19 |
2019-04-25 |
Eleusis Benefit Corporation, Pbc |
Methods and systems for enhancing safety of psychedelic drug therapies
|
|
US11491120B2
(en)
|
2017-11-09 |
2022-11-08 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
WO2019099568A1
(en)
|
2017-11-14 |
2019-05-23 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
MX2020006650A
(es)
|
2017-12-22 |
2020-11-06 |
Janssen Pharmaceuticals Inc |
Esketamina para el tratamiento de la depresión.
|
|
PL3505157T3
(pl)
|
2017-12-29 |
2022-04-11 |
Celon Pharma S.A. |
Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
|
|
KR20260028033A
(ko)
|
2018-01-10 |
2026-03-03 |
엑스더블유파마 리미티드 |
케타민의 전구약물, 및 이의 조성물 및 용도
|
|
AU2019223014B2
(en)
|
2018-02-21 |
2024-10-17 |
Orphai Therapeutics Inc. |
Combination therapy with apilimod and glutamatergic agents
|
|
US11980617B2
(en)
|
2018-03-16 |
2024-05-14 |
Intra-Cellular Therapies, Inc. |
Methods of treating acute depression and/or acute anxiety
|
|
WO2019186357A1
(en)
|
2018-03-26 |
2019-10-03 |
Cellix Bio Private Limited |
Compositions and methods for the treatment of neurological diseases
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
CA3099293A1
(en)
|
2018-05-04 |
2019-11-07 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
US11766409B2
(en)
|
2018-05-31 |
2023-09-26 |
The University Of Queensland |
Core-shell polymer nanoparticle
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
ES3004544T3
(en)
|
2018-06-27 |
2025-03-12 |
Bioxcel Therapeutics Inc |
Film formulations containing dexmedetomidine and methods of producing them
|
|
BR112020023882A2
(pt)
|
2018-06-27 |
2021-02-09 |
Clexio Biosciences Ltd. |
método para tratar transtorno depressivo maior
|
|
EP3829539A4
(en)
|
2018-08-02 |
2022-05-04 |
Taiwan Liposome Company, Ltd. |
DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
WO2020041329A1
(en)
|
2018-08-20 |
2020-02-27 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
EP3628313B1
(en)
|
2018-09-28 |
2025-02-12 |
Novohale Therapeutics, LLC |
Ketamine composition for use in a method of treatment of depression by pulmonary administration
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
US20210308040A1
(en)
|
2018-10-26 |
2021-10-07 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
WO2020089897A1
(en)
|
2018-10-29 |
2020-05-07 |
Hadasit Medical Research Services & Development Limited |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
WO2020106927A1
(en)
|
2018-11-21 |
2020-05-28 |
Certego Therapeutics |
Gaboxadol for reducing risk of suicide and rapid relief of depression
|
|
FI3908570T3
(fi)
|
2019-01-11 |
2024-02-13 |
Alar Pharmaceuticals Inc |
Ketamiinipamoaatti ja sen käyttö
|
|
SG11202107978RA
(en)
|
2019-01-23 |
2021-08-30 |
Univ Michigan Regents |
Methods and system for the reconstruction of drug response and disease networks and uses thereof
|
|
WO2020168213A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
WO2020178653A1
(en)
|
2019-03-05 |
2020-09-10 |
Janssen Pharmaceuticals, Inc. |
Esketamine for the treatment of depression
|
|
EP4230195A1
(en)
|
2019-03-07 |
2023-08-23 |
Arbormentis LLC |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
|
|
WO2020190997A1
(en)
|
2019-03-18 |
2020-09-24 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
BR112021019190A2
(pt)
|
2019-04-17 |
2021-11-30 |
Lts Lohmann Therapie Systeme Ag |
Sistema terapêutico transdérmico
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US12589083B2
(en)
|
2019-05-07 |
2026-03-31 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
US20220202742A1
(en)
|
2019-05-07 |
2022-06-30 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
EP3976145B1
(en)
|
2019-05-31 |
2025-01-15 |
Celon Pharma S.A. |
An inhaler for electronically supervised parenteral administration of a pharmaceutical composition
|
|
WO2020239243A1
(en)
|
2019-05-31 |
2020-12-03 |
Celon Pharma S.A. |
Electronically supervised administration of a pharmaceutical composition
|
|
WO2020247615A1
(en)
|
2019-06-04 |
2020-12-10 |
Sermone Sandra |
Ketamine and ketamine/nap for treatment of adnp syndrome and related neurological conditions
|
|
CA3133012A1
(en)
|
2019-08-05 |
2021-02-11 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
JP2022546456A
(ja)
|
2019-08-28 |
2022-11-04 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
自殺傾向を含む大うつ病性障害を有する患者の治療のためのエスケタミン
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
US20220339123A1
(en)
|
2019-09-13 |
2022-10-27 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
MX2022004022A
(es)
|
2019-10-02 |
2022-05-18 |
Praxis Prec Medicines Inc |
Combinaciones de moduladores alostericos positivos del receptor de gaba-a y antagonistas de nmda, moduladores alostericos negativos de nmda o agonistas parciales de nmda.
|
|
EP4497471A3
(en)
|
2019-10-18 |
2025-03-12 |
Institute of Science and Technology Austria |
Stimulation of neuronal plasticity
|
|
US20220378777A1
(en)
|
2019-10-31 |
2022-12-01 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
US20220401366A1
(en)
|
2019-11-15 |
2022-12-22 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
WO2021101867A1
(en)
|
2019-11-18 |
2021-05-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
AU2020386445B2
(en)
|
2019-11-19 |
2025-12-18 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
WO2021121366A1
(en)
|
2019-12-20 |
2021-06-24 |
Alar Pharmaceuticals Inc. |
Long-acting injectable formulations of ketamine pamoate salts
|
|
US12478592B2
(en)
|
2019-12-30 |
2025-11-25 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating neuropsychiatric or neurological conditions
|
|
US12268658B2
(en)
|
2019-12-30 |
2025-04-08 |
Clexio Biosciences Ltd. |
Dosage regime with esketamine for treating major depressive disorder
|
|
PH12022551856A1
(en)
|
2020-01-22 |
2024-01-03 |
Seelos Therapeutics Inc |
Reducing side effects of nmda antagonists
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
US20210308075A1
(en)
|
2020-04-07 |
2021-10-07 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
MX2022014599A
(es)
|
2020-05-20 |
2022-12-16 |
Certego Therapeutics Inc |
Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
|
|
EP4157244A4
(en)
|
2020-06-02 |
2024-07-17 |
IX Biopharma Limited |
METHODS OF TREATING MAJOR DEPRESSIVE DISORDER AND TREATMENT-RESISTANT DEPRESSION
|
|
WO2021255522A1
(en)
|
2020-06-19 |
2021-12-23 |
Guangzhou Dazhou Biomedicine Ltd. |
Transdermal drug delivery system for ketamine
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
IL300547A
(en)
|
2020-08-18 |
2023-04-01 |
Oakwood Laboratories LLC |
Microsphere formulations comprising ketamine and methods for their production and use
|
|
US20230375561A1
(en)
|
2020-09-30 |
2023-11-23 |
Rima F. Kaddurah-Daouk |
Methods for identification, stratification, and treatment of cns diseases
|
|
JP2023548215A
(ja)
|
2020-11-09 |
2023-11-15 |
エルテーエス ローマン テラピー－ジステーメ アーゲー |
経口薄フィルム
|
|
WO2022109165A1
(en)
|
2020-11-18 |
2022-05-27 |
Indiana University Research And Technology Corporation |
Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
US11690811B2
(en)
|
2021-08-13 |
2023-07-04 |
XWPharma Ltd. |
Pharmaceutical compositions and oral dosage forms of ketamine derivatives
|
|
US20230144704A1
(en)
|
2021-11-05 |
2023-05-11 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
US20240009145A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|